Bone augmentation utilizing muscle-derived progenitor compositions, and treatments thereof

A method of augmenting bone mass or density in a mammalian subject:

• (a) isolating skeletal muscle cells from a mammal,
• (b) cooling the cells to a temperature lower than 10° C. and storing the cells for 1-7 days;
• (c) suspending the mammalian skeletal muscle cells in a first cell culture container between 30 and 120 minutes;
• (d) decanting the media from the first cell culture container to a second cell culture container;
• (e) allowing the remaining cells in the media to attach to the walls of the second cell culture container;
• (f) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are muscle derived progenitor cells (MDCs);
• (g) culturing the cells to expand their number;
• (h) freezing the MDCs to a temperature below −30° C.;
• and
• (i) thawing the MDCs and administering the MDCs to a bone to be augmented in the mammalian subject;
• thereby, augmenting bone mass or density in the mammalian subject.

A method of improving at least one symptom associated with bone disease, defect or pathology in a mammalian subject in need thereof comprising:

• (a) isolating skeletal muscle cells from a mammal,
• (b) suspending the mammalian skeletal muscle cells in a first cell culture container for between 30 and 120 minutes;
• (c) decanting the media from the first cell culture container to a second cell culture container;
• (d) allowing the remaining cells in the media to attach to the walls of the second cell culture container;
• (e) isolating the cells from the walls of the second cell culture container, wherein the isolated cells are MDCs;
• and
• (f) administering the MDCs to a bone suffering from the bone defect, disease or pathology of the mammalian subject;
• thereby, improving at least one symptom associated with bone disease, defect or pathology in a mammalian subject in need thereof.

A method of treating a bone disease, defect or pathology in a mammalian subject in need thereof comprising:

• (a) plating a suspension of skeletal muscle cells from mammalian skeletal muscle tissue in a first container to which fibroblast cells of the skeletal muscle cell suspension adhere,
• (b) re-plating non-adherent cells from step (a) in a second container, wherein the step of re-plating is after 15-20% of cells have adhered to the first container;
• (c) repeating step (b) at least once;
• and
• (d) isolating the skeletal muscle-derived MDCs and administering the MDCs to a bone suffering from the bone defect, disease or pathology of the mammalian subject;
• thereby, treating urinary tract disease in a mammalian subject in need thereof.

A method of improving at least one symptom associated with bone disease, defect or pathology in a mammalian subject in need thereof comprising:

• (a) plating a suspension of skeletal muscle cells from skeletal muscle tissue in a first container to which fibroblast cells of the skeletal muscle cell suspension adhere,
• (b) re-plating non-adherent cells from step (a) in a second container, wherein the step of re-plating is after 15-20% of cells have adhered to the first container;
• (c) repeating step (b) at least once;
• (d) isolating the skeletal muscle-derived MDCs and administering the MDCs to a bone suffering from the bone defect, disease or pathology of the mammalian subject;
• thereby, improving at least one symptom associated with bone disease, defect or pathology in the mammalian subject in need thereof.

A method of treating a bone defect, disease or pathology in a mammalian subject in need thereof comprising administering a cell population containing muscle-derived cells (MDCs) to a bone suffering from the bone defect, disease or pathology of the mammalian subject, wherein the cell population containing MDCs has been obtained by a process comprising:

• (a) suspending cells isolated from mammalian skeletal muscle in a first cell culture container for a duration sufficient to adhere a first cell population to the container and to leave a second cell population unadhered and in a culture medium in the container;
• (b) transferring the culture medium and second cell population from the first cell culture container to a second cell culture container;
• (c) allowing cells from the second cell population to attach to the second cell culture container;
• and
• (d) isolating the cells attached to the second cell culture container to obtain said cell population containing MDCs.

A method for preparing a cell population containing muscle derived cells (MDCs) useful for administration to treat a bone defect, disease or pathology in a mammalian subject, comprising:

• (a) suspending cells isolated from mammalian skeletal muscle in a first cell culture container for a duration sufficient to adhere a first cell population to the container and to leave a second cell population remaining unadhered and in a culture medium in the container;
• (b) transferring the culture medium and second cell population from the first cell culture container to a second cell culture container;
• (c) allowing cells from the second cell population to attach to the second cell culture container;
• and
• (d) isolating the cells attached to the second cell culture container to obtain said cell population containing MDCs.